JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
Allist Pharmaceuticals, Inc.
Travera Inc
Cybrexa Therapeutics
Travera Inc
Revolution Medicines, Inc.
INSYS Therapeutics Inc
Delcath Systems Inc.